BDSI buys US rights to BEMA (bioerodible mucoadhesive disc) drug tech
This article was originally published in Clinica
Executive Summary
BioDelivery Sciences International (BDSI) has acquired the US rights to the BEMA (bioerodible mucoadhesive disc) drug delivery technology developed by biopharmaceutical company QLT for $3m. BDSI has also agreed to pay QLT up to $4m for achieving certain milestones, one of these being the NDA approval of BDSI's first BEMA product.